Advertisement
IXJ vs XLV
Which ETF would AI Choose? iShares Global Healthcare ETF (IXJ) vs. Health Care Select Sector SPDR Fund (XLV)
1) Key Takeaways
- Geographic scope differs sharply: IXJ holds global healthcare stocks across roughly 70% U.S. and 30% international exposure, while XLV is a U.S.-only portfolio drawn from the S&P 500.
- Cost is a clear differentiator: XLV charges a 0.08% expense ratio versus approximately 0.38% for IXJ, giving XLV a meaningful long-term cost advantage.
- Both are passive, market-cap-weighted funds with heavy overlap in large-cap pharmaceuticals and biotechnology, but XLV is far more concentrated in a handful of U.S. mega-caps.
- Liquidity favors XLV: with materially larger assets under management (AUM) and trading volume, XLV generally offers tighter spreads than IXJ.
- Diversification favors IXJ: its inclusion of Swiss, UK, Japanese, and other developed-market names reduces single-country and single-stock concentration.
- Tickeron AI Verdict: XLV — on balance, its lower cost, deeper liquidity, and concentrated exposure to market-leading U.S. healthcare names give it the edge in this comparison.
2) Introduction
Healthcare is one of the most closely watched sectors in the current environment, as investors weigh drug-pricing policy, an aging global population, and a wave of innovation in GLP-1 (glucagon-like peptide-1) weight-loss and obesity treatments. The iShares Global Healthcare ETF and the Health Care Select Sector SPDR Fund are two of the most established ways to gain diversified exposure to this space, yet they serve different purposes. XLV delivers a concentrated, low-cost bet on U.S. healthcare giants within the S&P 500, while IXJ broadens the mandate across global developed markets. For investors building a sector sleeve, understanding these structural differences is essential to proper ETF comparison and relative positioning.
3) iShares Global Healthcare ETF (IXJ) Overview
The iShares Global Healthcare ETF (IXJ) is a passively managed fund that seeks to track the S&P Global 1200 Health Care (Sector) Capped Index, a market-cap-weighted benchmark of large-capitalization healthcare companies across global developed markets. The fund holds roughly 120 companies and offers meaningful geographic diversification: the United States represents about 70% of assets, with Switzerland, the United Kingdom, Japan, Denmark, and France contributing most of the remainder.
Top holdings include Eli Lilly, Johnson & Johnson, AbbVie, Merck, and UnitedHealth Group, alongside non-U.S. leaders such as Roche, Novartis, and AstraZeneca. By industry, pharmaceuticals dominate at roughly 42% of assets, followed by healthcare equipment and supplies, biotechnology, healthcare providers and services, and life sciences tools. The expense ratio is approximately 0.38%, reflecting the added cost of maintaining global coverage. Launched in 2001, IXJ suits investors seeking international diversification within a single healthcare sleeve.
4) Health Care Select Sector SPDR Fund (XLV) Overview
The Health Care Select Sector SPDR Fund (XLV) is a passively managed fund that tracks the Health Care Select Sector Index, which comprises the healthcare constituents of the S&P 500. The portfolio holds about 60 to 65 U.S. large-cap companies and is overwhelmingly domestic, with nearly all assets invested in the United States. As one of the oldest and largest healthcare ETFs — launched in 1998 — XLV benefits from a very low 0.08% expense ratio and deep secondary-market liquidity.
Top holdings are heavily weighted toward U.S. mega-caps: Eli Lilly (roughly 15%), Johnson & Johnson, AbbVie, UnitedHealth Group, and Merck, with Thermo Fisher Scientific, Amgen, Gilead Sciences, Abbott Laboratories, and Pfizer rounding out the top ten. By industry, pharmaceuticals, biotechnology, and healthcare equipment and supplies are the largest segments. The fund employs a full-replication strategy and is non-diversified, meaning a handful of names carry outsized influence on returns.
5) Industry and Thematic Backdrop
Both funds are shaped by the same macro and regulatory forces. GLP-1 obesity and diabetes drugs have become a dominant earnings driver, concentrating sector momentum in innovators such as Eli Lilly. Simultaneously, drug-pricing reform, patent expirations, and Medicare (the U.S. federal health insurance program) policy uncertainty create a more mixed outlook for traditional pharmaceutical and managed-care names. Interest-rate expectations also matter: healthcare is often treated as a defensive, bond-proxy sector, so rising or falling yields can influence relative positioning versus growth-oriented equity segments. Finally, demographic tailwinds from aging populations support durable long-term demand, while geopolitical and supply-chain factors add variance to the global names held by IXJ. These catalysts make an ETF comparison of geographic scope and concentration especially relevant today.
6) Performance and Positioning Comparison
In recent weeks and across recent market cycles, XLV and IXJ have tended to move in tandem because their largest holdings overlap. However, XLV's higher concentration in Eli Lilly and other U.S. large caps has amplified its sensitivity to GLP-1-driven momentum, while IXJ's broader base — including European pharmaceutical and life-science names — has moderated both upside and downside. XLV's lower cost and heavier mega-cap weighting generally support stronger net returns during U.S.-led rallies, whereas IXJ's international sleeve can cushion performance when the U.S. dollar weakens or when foreign healthcare names outperform. On volatility, XLV's concentrated, non-diversified structure can carry slightly higher single-stock risk, while IXJ's wider footprint offers a smoother, more globally balanced exposure profile.
7) AI Screener
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By surfacing trade ideas, trending names, breakout candidates, and market opportunities more efficiently than manual screening, the tool supports faster, data-informed decision-making. Explore the AI Screener to refine your own sector and ETF comparison workflows.
8) Tickeron AI Verdict
Weighing structural strength, cost efficiency, diversification, trend consistency, and risk exposure, Tickeron's AI would currently favor XLV. Its materially lower expense ratio, deeper liquidity, and concentrated exposure to the market-leading U.S. healthcare franchises driving current sector momentum give it a probabilistic edge over IXJ. IXJ remains a compelling choice for investors prioritizing global diversification and reduced single-country risk, but on a relative basis, XLV's combination of cost and concentration aligns more closely with prevailing momentum conditions.
9) Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IXJ is a StrongBuy and XLV is a Buy.
IXJ in upward trend: 10-day moving average moved above 50-day moving average on October 19, 2026
The 10-day moving average for IXJ crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on IXJ as a result. In 75 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for IXJ just turned positive on October 12, 2026. Looking at past instances where IXJ's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
IXJ moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where IXJ advanced for three days, in 256 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IXJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
IXJ broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IXJ entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
XLV in upward trend: 10-day moving average moved above 50-day moving average on October 15, 2026
The 10-day moving average for XLV crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on XLV as a result. In 78 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for XLV just turned positive on October 09, 2026. Looking at past instances where XLV's MACD turned positive, the stock continued to rise in 39 of 48 cases over the following month. The odds of a continued upward trend are 81%.
XLV moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 263 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 219 of 271 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 67 cases where XLV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
XLV broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
| IXJ | XLV | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 76% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 84% |
| Advances ODDS (%) | 6 days ago 80% | 6 days ago 81% |
| Declines ODDS (%) | 2 days ago 76% | 2 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 72% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 81% |
Advertisement
IXJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, IXJ has been closely correlated with LLY. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if IXJ jumps, then LLY could also see price increases.
XLV and
Correlation & Price change
A.I.dvisor indicates that over the last year, XLV has been closely correlated with LLY. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if XLV jumps, then LLY could also see price increases.